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SUMMARY
Colorectal cancers (CRC) are thought to have genetic instability in the form of either
microsatellite instability (MSI) or chromosomal instability (CIN). Recently, tumours
have been described without either MSI or CIN, that is, microsatellite and chromo-
some stable (MACS) CRCs. We investigated the (i) frequency of the MACS-CRCs
and (ii) whether this genotype predicted responsiveness to neoadjuvant chemoradio-
therapy. To examine the frequency of MACS-CRCs, DNA content (ploidy) was
examined in 89 sporadic microsatellite-stable CRCs using flow cytometry. The
tumours were also screened for mutations in KRAS/BRAF/TP53/PIK3CA by QMC-
PCR. To examine the value of tumour ploidy in predicting response to chemoradio-
therapy, DNA content was tested in a separate group of 62 rectal cancers treated
with neoadjuvant chemoradiotherapy. Fifty-one of 89 CRCs (57%) were aneuploid
and 38 (43%) were diploid. There was no significant association between mutations
in TP53/KRAS/BRAF/PIK3CA and ploidy. Testing of association between mutations
revealed only mutual exclusivity of KRAS/BRAF mutation (P < 0.001). Of the 62
rectal cancers treated with neoadjuvant chemoradiotherapy, 22 had responded
(Mandard tumour regression grade 1/2) and 40 failed to respond (Grade 3–5).
Twenty-five of 62 (40%) tumours were diploid, but there was no association
between ploidy and response to therapy. We conclude that MACS-CRCs form a
significant proportion of microsatellite-stable CRCs with a mutation profile overlap-
ping that of CRCs with CIN. A diploid genotype does not, however, predict the
responsiveness to radiotherapy.
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The role of genomic instability in the development of cancer
is a contentious issue. Some have argued that onset of geno-
mic instability, through mutation of ‘caretaker’ genes which
are responsible for the maintenance of genomic integrity,
results in an increased mutation rate, and this is essential to
the carcinogenetic process (Levitt & Hickson 2002). Others,
however, have argued that tumour evolution through waves
of mutation-driven clonal expansion is sufficient for tumour
development without the requirement of genomic instability
(Sieber et al. 2003). Irrespective of its precise role in tumour
development, genomic instability is very commonly seen in
many different cancers and it accelerates the rate of tumour
development.
Sporadic colorectal cancers (CRCs) are usually considered
to have two main types of genomic instability, that is, mi-
crosatellite instability (MSI) or chromosomal instability
(CIN) (Ilyas et al. 1999; Jass 2007). Colorectal cancers
acquire MSI as a result of loss of mismatch repair function
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arising from mutational or epigenetic inactivation of any
one of four genes – MLH1, MSH2,PMS2 and MSH6
(Thibodeau et al. 1993; Karran 1995; Lothe 1997; Abdel-
Rahman et al. 2006). Loss of mismatch repair function
results in a failure to repair base-pair mismatches, and small
scale insertion/deletion mutations resulting in genome-wide
mutations of these types. Karyotypically, however, CRCs
with MSI (MSI-CRCs) have a diploid or near-diploid DNA
content (Kouri et al. 1990; Frei 1992; Curtis et al. 2000).
CIN is more or less mutually exclusive with MSI, and it is
characterised by large-scale genomic changes including dele-
tions, amplifications and gains/losses of whole chromo-
somes. The cause of CIN in CRCs is not known although a
number of candidates such as APC, AXIN2, TP53, AUR-
ORA A and FBXW7 have been proposed (Williams et al.
1997; Fodde et al. 2001; Rajagopalan et al. 2004; Hadjih-
annas et al. 2006; Baba et al. 2009). Those CRCs with CIN
(CIN-CRCs) characteristically show aneuploidy on examina-
tion of DNA content (Pino & Chung 2010).
Around 10–15% of sporadic CRCs show MSI whilst the
remainder are microsatellite stable and are usually consid-
ered to show CIN. However, prior to the discovery of mis-
match repair deficiency and MSI, tumour DNA content was
commonly evaluated and a review of these published studies
shows that the proportion of diploid tumours reported var-
ied from 11% to 64% (Heimann et al. 1990; Armitage
et al. 1991; Tang et al. 1995; Flyger et al. 1999). A recent
meta-analysis of these studies estimated that, of 5478
patients, 42% showed a diploid genotype (Araujo et al.
2007). If the cases with probable MSI are removed, then the
data would suggest that a significant proportion of all CRCs
have neither MSI nor CIN (henceforth referred to as micro-
satellite and chromosomal stable, MACS). This point is rein-
forced in studies which have exclusively tested rectal
cancers. Of the tumours located at this site, only 2–3% will
have MSI (Hutchins et al. 2011) but the reported frequency
of diploid rectal tumours is 30–64% (Fisher et al. 1989;
Heimann et al. 1990; Michelassi et al. 1992). There have
been some reports of MACS-CRCs although these are
relatively few (Georgiades et al. 1999; Hawkins et al. 2001;
Silver et al. 2011). Despite these reports and the circumstan-
tial evidence from earlier studies, a dogma has emerged that
CRCs must have one or other form of genomic instability
and recent reviews have cited the frequency of CIN as
around 85% (Fearon 2011; Pritchard & Grady 2011).
The MACS-CRCs therefore may form a third group
which is distinct from CRC with MSI and CIN. As well as
having implications for cancer theory, this may have clinical
implications. MSI-CRCs have distinct clinico-pathological
features including, amongst others, right-sided location and
a comparatively good clinical outcome. Conversely, CIN-
CRCs have a left-sided predominance and a generally poorer
outcome than MSI-CRCs. As MACS-CRCs are a relatively
poorly described group, their clinico-pathological correlates
are also poorly described.
As well as providing prognostic information, genotypic
analysis of tumours may predict responsiveness to specific
therapies. For example, MSI-CRCs reportedly have poor
response to 5-fluoro-uracil but better response to irinotecan
than their CIN counterparts (Ribic et al. 2003; Bertagnolli
et al. 2009). In recent years, neoadjuvant (chemo)radiother-
apy has become commonplace for rectal CRCs. Approxi-
mately 15–25% of these tumours undergo marked
regression (Mandard grade 1 or 2) although currently it is
impossible to predict which tumours will respond (Vecchio
et al. 2005; Suarez et al. 2008; Dhadda et al. 2009, 2011).
If responsiveness to radiation could be predicted with cer-
tainty, it would allow a significant proportion to patients to
avoid major surgery. We hypothesised that MACS-CRCs
may respond differently to radiation than CIN-CRCs. If so,
tumour ploidy could be used as a predictive test for radia-
tion responsiveness.
Given the relative paucity of knowledge about the MACS-
CRCs, we firstly evaluated the DNA content and mutation
profile in an unselected series of CRCs which were shown to
be microsatellite stable. To test our hypothesis that MACS-
CRCs and CIN-CRCs may have different responses to radia-
tion, we then evaluated the DNA content of preradiotherapy
biopsies from a series of rectal cancers and correlated
tumour regression with ploidy status.
Materials and methods
Sample collection
Two sample sets were tested. Sample set 1 was used for the
study to evaluate the DNA content and mutation profiles of
CRCs. A total of 100 anonymised cases of sporadic CRC
who underwent surgery between 2004 and 2005 were
selected from the archives of the Nottingham University
Hospitals Department of Histopathology. Only cases in
which clinic-pathological data were available were selected,
and one tumour block (containing at least 50% tumour)
from each case was chosen for testing. Of these, 11 cases
were excluded due to either the presence of microsatellite
instability (see below) or PCR failure. The remaining
89 cases underwent DNA content analysis and mutation
profiling.
Sample set 2 was used only for the study to evaluate the
association between DNA content (ploidy) and regression
following neoadjuvant chemoradiotherapy (CRT). A series
of 62 cases were selected from a previously reported series
(Dhadda et al. 2011). Of these, 22 cases had shown a
marked response (i.e. Mandard tumour regression grade 1
or 2) whilst 40 cases had shown little or no response (Man-
dard tumour regression grade 3–5). If ploidy is associated
with responsiveness to CRT, one would expect a non-
random distribution of aneuploid and diploid genotypes
between the responders and non-responders. The pre-CRT
biopsies from these cases were retrieved from the archives of
the Nottingham University Hospitals Department of Histo-
pathology and were tested for DNA content analysis. All
experimental work was undertaken with local institutional
approval.
International Journal of Experimental Pathology, 2014, 95, 16–23
MACS and CIN in colorectal cancer 17
Molecular analysis of tumour samples
DNA extraction. DNA was extracted from formalin-fixed
paraffin-embedded (FFPE) tissue from all cases of sample set
1 as previously described (Fadhil et al. 2010). Four 10-lm-
thick sections were de-waxed in xylene and underwent stan-
dard proteinase K digestion before extraction through
DNeasy columns (QIAGEN, Hilden, Germany) in accor-
dance with the manufacturer’s instructions. Template DNA
was diluted to a final concentration of 20 ng/ll.
Testing for microsatellite instability. All cases in sample set
1 were screened for the presence of microsatellite instability
(MSI) which was performed by PCR followed by high-
resolution melting (HRM) analysis as previously described
(Fadhil et al. 2012). A panel of six markers (BAT25, BAT26,
NR21, NR22, NR24 and B-CAT25) was used to evaluate
instability at mononucleotide repeat sequences. PCR was car-
ried out in 10 ll reaction containing 1X Sensi- MixTM HRM
Kit (Bioline, London, UK), 0.25 lM concentration of each
primer, 1X LC green Plus+ dye (Idaho Technology, Salt
Lake City, UT, USA) and 20 ng DNA template. HRM was
performed immediately after PCR and consisted of one cycle
of [(95 °C for 15 s)/(55 °C for 1 min)] followed by slow
ramping up (at 0.03 degrees/s) to 95 °C during which fluo-
rescent data were captured. Thermal cycling and HRM was
performed on the AB 7500 fast PCR machine (ABI Biosys-
tems, Paisely, UK) as previously described. Data were analy-
sed using the Applied Biosystems High-Resolution Melting
software v2.0. Samples were only regarded as showing MSI
if there was instability at two or more of six markers.
Mutation analysis. All cases in sample set 1 were screened
for mutation in the hotspots of KRAS (Codons 12/13, 61
and 146), BRAF (Codon 600 and exon 11) and PIK3CA
(exon 1, exon 9 and exon 20) using the quick multiplex
consensus (QMC) protocols followed by HRM analysis as
previously described (Fadhil et al. 2010). Samples were
screened for mutation in the TP53 mutation hotspot (exon
5–8) using standard PCR followed by HRM as previously
described (Fadhil et al. 2012). Thermal cycling, HRM and
data analysis were performed on the AB 7500 fast
PCR machine using the using the Applied Biosystems High-
Resolution Melting software v2.0. All primer sequences are
given in Supplementary Table S1.
Ploidy analysis
Isolation of nuclei. The DNA content of tumour cells was
measured by flow cytometry using FFPE tumour tissue. All
tumours (in both sample sets) were tested, and whole nuclei
were extracted using a modification of the method of Hed-
ley et al. (1983). Following pathology review (to choose the
block with the highest proportion of tumour cells), a single
30-lm-thick section was cut. Sections were de-waxed in
xylene and rehydrated in graded alcohols. The sections were
washed in distilled water (twice) and then digested at 37 °C
in 1 ml of 1.5% pepsin (p-7000; Sigma Aldrich, Gillingham,
UK) in 0.9% NaCl (pH 1.5) for 2 h with intermittent vortex
mixing. Following digestion, the sections were vigorously
vortexed for 60 s to release the nuclei. The suspended nuclei
were counted using a Neubauer chamber to ensure that
there were more than 106/ml nuclei present. The tissues
were then passed through a 70-lm nylon filter (Becton Dick-
inson) and centrifuged at 239 g for 5 min. The supernatant
was removed and the pellet was re-suspended and washed
twice in PBA (0.1% BSA in PBS) to remove residual pepsin.
The cell pellet then was re-suspended in the staining solution
in the flow cytometer tubes.
Flow cytometry. Prior to analysis by flow cytometry, the
suspended nuclei were stained by incubation for 30 min with
propidium iodide and Rnase (both sigma) at a respective final
concentration of 1 and 10 mg/ml in PBA. Flow cytometry
was performed on a Beckman Coulter FC500 flow cytome-
ter, and experiments were performed following the guidelines
of Ormerod et al. (1998), using doublet discrimination on a
DNA fluorescence area vs. peak plot. Fluorescence from a
minimum of 30,000 events per sample was captured over
1024 channels, and samples were deemed unacceptable if
background aggregates and debris (i.e. sub-G1 fraction and
clumps) comprised >20% of the total events.
Each tumour sample consists of tumour cells together
with stromal cells and lymphocytes. The non-tumour cells
are diploid and were used to set internal parameters and as
internal controls. The photomultiplier tube (PMT) voltage
of the flow cytometer was adjusted so that the G0/G1 peak
of the non-tumour cells was captured at a channel number
>200. The G0/G1(2c) and G2/M (4c) peaks of the internal
controls were assigned to the channel with the maximum
fluorescence for each, and a sample was acceptable if there
was linearity between the G0/G1 and G2/M peaks (i.e. the
ratio was between 1.95 and 2.05), the G2/M peak did not
exceed 10% of the total events, the proportion of events at
>6c (i.e. clumps) was not >1% and the co-efficient of varia-
tion of the G0/G1peak for the internal controls was <6%.
Data analysis. Data analysis was performed using the WEA-
SEL v2.7 software (Walter and Eliza Hall Institute, Parkille,
Australia; www.wehi.edu.au). Every single sample had easily
identifiable 2c and 4c peaks for the internal non-tumour
cells. The DNA index (DI) for additional peaks was calcu-
lated as the ratio of the channel position of the tumour G0/
G1 peak to the control G0/G1 peak. Tumour samples were
considered diploid/near diploid when the DI was between
0.9 and 1.1 and aneuploid when the DI was outside these
ranges. If the G2/M (4c) peak of the controls comprised
more than 10% of the total and there was a corresponding
8c peak, the tumour was deemed as tetraploid.
Statistical analyses
Statistical analysis was performed using the GRAPHPAD PRISM
software package (GraphPad Software Inc., La Jolla, CA,
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USA). Categorical data were tested for association using a
two-sided Fisher’s exact test. Nonparametric continuous data
were analysed using the Mann–Whitney test. In all cases,
P-values < 0.05 was considered as statistically significant.
Results
Screening cases for microsatellite instability
A total of 100 cases were included in sample set 1, and
these were tested for the presence of microsatellite instabil-
ity. Each tumour was tested using a panel of six mononucle-
otide markers. Of the tumours tested, eight showed
instability in over two of the markers (Figure 1a) and were
excluded from sample set 1.
Flow cytometry
Of the 92 tumours tested for flow cytometry, reliable data
could not be obtained for three of these and these were
excluded from further analysis. Reliable data were obtained
from the remaining 89 tumours, and there were three dis-
tinct patterns seen. Firstly, there were samples in which a
single G0/G1 peak was seen with a smaller G2/M peak (Fig-
ure 1b) and this was deemed to be a diploid tumour. A sec-
ond pattern was that of two peaks at G1/G0 that lay very
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Figure 1 Evaluation of the DNA content of colorectal tumours. Firstly, the tumours were screened for the presence of microsatellite
instability (MSI) by PCR/high-resolution melting (HRM) for six separate mononucleotide markers. (a) shows data for BAT26 and
BCAT25 markers. The microsatellite-stable cases show similar patterns of melting (circled) whilst two cases are shown (each in
duplicate and denoted by the arrows) in which there is instability at these markers resulting in aberrant melting. (b)–(d) show the
three patterns seen when evaluating microsatellite-stable cases by flow cytometery. (b) shows a diploid pattern in which the tumour
cells and stromal cells lie within a single dominant diploid peak. The arrow indicates the G2/M peak (representing 4c DNA content).
(c) shows a ‘near-diploid’ pattern in which a separate peak (single arrow) is clearly discernible from the dominant G0/G1 peak, but
the DNA index of this is >1.1. The G2/M peaks are shown by the double arrow. (d) the arrow shows a clearly aneuploid peak
which, in this case, has a DNA index of 1.6.
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close to each other with a ratio of 0.9:1.1 seen between the
two peaks. There were also two closely associated G2/M
peaks, and this pattern was deemed a ‘near-diploid’ tumour
(Figure 1c). The third pattern was that of an aneuploid pop-
ulation in which extra peaks were seen between the G0/G1
and G2/M peaks of the internal diploid controls. There was
usually just one extra peak although occasionally multiple
extra peaks were seen. These represented the G0/G1 peak of
an aneuploid population (Figure 1d).
Of the 89 microsatellite-stable CRCs tested, a total of 51
(57%) were aneuploid (i.e. CIN-CRCs) whilst 38 (43%)
were diploid or near diploid (i.e. MACS-CRCs). Thus, a
high proportion of the tumours tested were of the MACS
genotype, but there were no significant clinico-pathological
differences seen between CIN-CRCs and MACS-CRCs
(Table 1).
The mutation profile of CIN-CRCs and MACS-CRCs
All 89 tumours in the first series were screened for the pres-
ence of mutation in the hotspots of KRAS, BRAF, PIK3CA
and TP53 (Table 1). The frequency of mutations of the total
sample set was as follows: KRAS: 46%, BRAF: 10%,
PIK3CA: 15% and TP53: 61%. The frequency of mutation
is in line with what would be expected for an unselected ser-
ies of CRCs. Subgroup analysis and comparison of CIN-
CRCs with MACS-CRCs showed that generally there was a
similar mutation frequency within the two groups with no
significant difference emerging. Of interest, however, was
that 69% of CIN-CRCs contained TP53 mutation whilst
this was seen in 50% of the MACS-CRCs. This was no sta-
tistically significant (P = 0.08) but raises the possibility that
TP53 mutation may be permissive for the aneuploid state as
has been previously suggested and consistent with its
proposed role as a ‘caretaker’ gene. Similarly, 39% of CIN-
CRCs were mutant for KRAS compared to 55% of MACS-
CRCs, suggesting a preference of the latter for development
along a KRAS-dependent pathway. Evaluation of the total
mutation burden showed that 5/51 (10%) CIN tumours did
not have mutation in any of these genes whilst, for the
MACS group, 8/38 (27%) tumours were wild type for these
genes. The difference was not statistically significant
(P = 0.22).
The association of mutations with each other was also
tested. In the group overall, there was the expected negative
association between mutation of KRAS and BRAF
(P = 0.001). Apart from this, there was no significant
association seen in either the overall group or either of the
subgroups (Table 2).
The association of DNA content with radiation
responsiveness
We had hypothesised that tumour responsiveness to radia-
tion may be predicted by DNA content. To test this, we
evaluated the DNA content of diagnostic biopsies from a
separate series of 62 rectal cancers. Of these, 22 had
responded (Mandard tumour regression grade 1 & 2) and
40 had shown little response (Mandard tumour regression
grade 3–5) following neoadjuvant chemoradiotherapy. Over-
all, 35/62 (60%) cases were aneuploid whilst 25/60 (40%)
cases were diploid. Of the responders, 12/22 (54%) were
CIN-CRCs and 10/22 (46%) were MACS-CRCs. Of the
non-responders, 25/40 (62%) were CIN-CRCs and 15/40
(38%) were MACS-CRCs. Subgroup analysis, however,
failed to show any association between tumour DNA
content and response to the radiotherapy.
Discussion
In this study, we evaluated the DNA content of microsatel-
lite-stable CRCs to evaluate the proportion of aneuploid
and diploid tumours. The aneuploid group were deemed to
show chromosomal instability (CIN) and were therefore des-
ignated as CIN-CRCs. The diploid group, because of their
stable karyotype, were considered to be both microsatellite
and chromosomal stable (MACS) and were designated as
MACS-CRCs. Two independent sets of tumours were
Table 1 Clinico-pathological features and mutational profile of
CIN-CRCs and MACS-CRCs
CIN-CRC
(%)
MACS-CRC
(%) P-value
Total
sample (%)
Sex
M 32 (63) 22 (58) 0.6 54 (61)
F 19 (37) 16 (42) 35 (39)
Age
Median 66 73 0.06 70
IQR 58–78 66–78.5 62–78
Mean 67 71 69
Dukes’ stage
A/B 21 (48) 14 (44) 0.8 35 (46)
C/D 23 (52) 18 (56) 41 (54)
EMVI
V0 17 (36) 12 (39) 1.0 29 (37)
V1 30 (64) 19 (61) 49 (63)
Location
Right sided 16 (31) 12 (32) 1.0 28 (32)
Left sided 35 (69) 25 (68) 60 (68)
KRAS
Mutant 20 (39) 21 (55) 0.19 41 (46)
Wild type 31 (61) 17 (45) 48 (54)
BRAF
Mutant 5 (10) 4 (11) 1.00 9 (10)
Wild type 46 (90) 34 (89) 80 (90)
PIK3CA
Mutant 9 (18) 4 (11) 0.38 13 (15)
Wild type 42 (82) 34 (89) 76 (85)
TP53
Mutant 35 (69) 19 (50) 0.08 54 (61)
Wild type 16 (31) 19 (50) 35 (39)
EMVI, extramural vascular invasion; CIN, chromosomal instability;
CRCs, colorectal cancers; MACS, microsatellite and chromosome
stable.
Right sided = proximal to the splenic flexure; Left sided = distal to
the splenic flexure.
International Journal of Experimental Pathology, 2014, 95, 16–23
20 W. Fadhil et al.
analysed – a series of 89 colorectal tumours was tested to
test the association between ploidy and clinicopathological/
molecular features, and a second series of 62 rectal cancers
which had received neoadjuvant CRT was tested to ascer-
tain whether ploidy could predict responsiveness to radia-
tion.
Using flow cytometry to quantify the tumour DNA con-
tent, we found that MACS-CRCs comprised 43% of the first
sample set and 45% of the second sample set. Archival stud-
ies have reported the proportion of diploid tumours as rang-
ing from 20% to 60%, but it has always been greater than
the proportion of expected MSI-CRCs. Both of our sample
sets are consistent with the published literature and with
each other. All of our cases were reviewed to ensure a mini-
mum of 50% tumour cells within the samples tested. We
chose to use propidium iodide to stain the DNA rather than
DAPI as, in our hands at least, both gave identical results
during the optimisation of the flow cytometry protocol (data
not shown). We are therefore confident that our proportion
of MACS-CRCs is not due to false-negative flow cytometry
results. Our data strongly challenge the dogma that CRCs
can all be dichotomised into tumours which progress along
either the MSI or CIN pathway (Fearon 2011; Pritchard &
Grady 2011). We have shown that a significant proportion
of CRCs belong to a third group which involves neither
CIN nor MSI. These tumours may not have any genomic
instability or they may have a third form of genomic insta-
bility [such as that caused by POLE mutations (Palles et al.
2013; The Cancer Genome Atlas Network 2012)].
In sample set one, we sought to evaluate whether there
were any clinico-pathological or molecular differences
between MACS-CRCs and CIN-CRCs. Firstly, comparison
of the clinico-pathological features of MACS-CRCs with the
CIN-CRCs did not show any significant differences. Old
studies of tumour ploidy have found a significant association
of diploid tumours with the right side of the colon and with
better prognosis although these would have been obviously
confounded by the inclusion of tumours with MSI. Studies
that have evaluated MACS-CRCs specifically have published
mixed data with some reporting a left-sided predominance
of the MACS-CRCs or a poor prognosis whilst others have
not found these features (Hawkins et al. 2001; Silver et al.
2011).
Screening for mutation in four genes commonly mutated
in CRCs demonstrated no significant differences apart
from a slightly greater frequency of TP53 mutation in the
Table 2 Association of gene mutations in CIN-CRCs and MACS-CRCs
BRAF PIK3CA TP53
Mutant Wild type P-value Mutant Wild type P-value Mutant Wild type P-value
All cases
KRAS
Mutant 0 41 0.003 8 33 0.26 24 17 0.7
Wild type 9 39 5 43 30 18
BRAF
Mutant 1 8 1.00 6 3 1.00
Wild type 12 68 48 32
PIK3CA
Mutant 6 7 0.36
Wild type 48 28
CIN-CRCs
KRAS
Mutant 0 20 0.14 5 15 0.28 13 7 0.7
Wild type 5 26 4 27 22 9
BRAF
Mutant 1 4 1.00 3 2 0.64
Wild type 8 38 32 14
PIK3CA
Mutant 4 5 0.12
Wild type 31 11
MACS-CRC
KRAS
Mutant 0 21 0.03 3 18 0.61 11 10 1.00
Wild type 4 13 1 16 8 9
BRAF
Mutant 0 4 1.00 3 1 0.60
Wild type 4 30 16 18
PIK3CA
Mutant 2 2 1.00
Wild type 17 17
CIN, chromosomal instability; CRCs, colorectal cancers; MACS, microsatellite and chromosome stable.
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CIN-CRCs. This series of cases is of insufficient size to
pick up small or moderate differences in mutation fre-
quency between the two groups. Our data do show that,
for the genes tested, the differences between the two
groups are not stark and that whilst TP53 mutation may
be permissive for aneuploidy, it is not a major cause of
aneuploidy. The similarity in the mutation profiles of the
CIN-CRCs and the MACS-CRCs also suggests that
the events which lead to aneuploidy probably occur late in
the carcinogenetic process after these mutations are likely
to have occurred. This is consistent with data showing
that aneuploid clones rarely occur in early or intermediate
stage adenomas but can be identified in the late stage
adenomas (van den Ingh et al. 1985; Goh & Jass 1986;
Quirke et al. 1986).
We also investigated whether the MACS phenotype was
associated with responsiveness to neoadjuvant radiation
therapy in a separate set of rectal cancers. Around 15–25%
of rectal CRCs show a dramatic response to neoadjuvant
radiation therapy, and identification of the features predict-
ing responsiveness would be a major step forward in the
management of patients with rectal cancer. We hypothesised
that the DNA content may be associated with responsive-
ness, and thus, pre-radiotherapy diagnostic biopsies from
cases of responsive and non-responsive tumours were tested.
There was no difference in the rate of response between
CIN-CRCs and MACS-CRCs, leading us to conclude that
tumour ploidy is not associated with tumour response to
radiation.
In summary, we have demonstrated that MACS-CRCs
form a significant group in the microsatellite-stable CRCs.
The Fearon and Vogelstein model of colorectal tumourigene-
sis was postulated over 30 years ago and did not feature
tumour ploidy. This should be revisited and should include
three distinct groups, that is, MSI-CRC, CIN-CRC and
MACS-CRC within the classification. Whilst these groupings
may be associated with the biology of CRCs, they do not
influence the response to radiation therapy.
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